Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development

Cell Cycle

Volumn 11, Issue 6, 2012, Pages 1202-1216

  Caracciolo, Valentina ^a   Laurenti, Giulio ^b   Romano, Gaetano ^a   Carnevale, Vincenzo ^a   Cimini, Anna Maria ^b   Crozier Fitzgerald, Catena ^a   Gentile, Emilio ^a   Russo, Giuseppe ^a   Giordano, Antonio ^a,c  

^a Temple University   (United States)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

AKT; Cancer; Cdk7; Cdk9; Cell cycle; Drug development; Flavopiridol

Indexed keywords

CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; FLAVOPIRIDOL; PROTEIN KINASE B; RNA POLYMERASE II; ROSCOVITINE; SERINE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ACTIVATION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG DESIGN; ENZYME PHOSPHORYLATION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

EID: 84858719382     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.6.19663     Document Type: Article

References (76)

1. Graña X, De Luca A, Sang N, Fu Y, Claudio PP, Rosenblatt J, et al. PITALRE, a nuclear CDC2- related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci USA 1994; 91:3834-8; PMID:8170997; http://dx.doi.org/10.1073/pnas.91.9.3834.
2. Bagella L, MacLachlan TK, Buono RJ, Pisano MM, Giordano A, De Luca A. Cloning of murine CDK9/PITALRE and its tissue-specific expression in development. J Cell Physiol 1998; 177:206-13; PMID:9766517; http://dx.doi.org/ 10.1002/(SICI)1097-4652(199811)177:2〈206::AIDJCP2〉3.0.CO;2-R.
3. Bagella L, Stiegler P, De Luca A, Siracusa LD, Giordano A. Genomic organization, promoter analysis and chromosomal mapping of the mouse gene encoding Cdk9. J Cell Biochem 2000; 78:170-8; PMID:10797576; http://dx.doi.org/10.1002/(SICI)1097-4644(20000701)78:1〈170:: AID-JCB16〉3.0.CO;2-A.
4. Romano G, Kasten M, De Falco G, Micheli P, Khalili K, Giordano A. Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression. J Cell Biochem 1999; 75:357-68; PMID:10536359; http://dx.doi.org/10.1002/(SICI)1097-4644(19991201)75:3〈357::AIDJCB1〉 3.0.CO;2-K.
5. Romano G, Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle 2008; 7:3664-8; PMID:19029809; http://dx.doi.org/10.4161/cc.7.23.7122.
6. Simone C, Stiegler P, Bagella L, Pucci B, Bellan C, De Falco G, et al. Activation of MyoD-dependent transcription by Cdk9/cyclin T2. Oncogene 2002; 21:4137-48; PMID:12037670; http://dx.doi.org/10.1038/sj.onc.1205493.
7. Fu TJ, Peng J, Lee G, Price DH, Flores O. Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription. J Biol Chem 1999; 274:34527-30; PMID:10574912; http://dx.doi.org/10.1074/jbc.274.49. 34527.
8. Weinmann H, Metternich R. Drug discovery process for kinase inhibitors. Chembiochem 2005; 6:455- 9; PMID:15742380; http://dx.doi.org/10.1002/cbic. 200500034.
9. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30:630- 41; PMID:16236519; http://dx.doi.org/10.1016/j.tibs. 2005.09.005.
10. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007; 17:60-5; PMID:17208431; http://dx.doi.org/10.1016/j. gde.2006.12.008.
11. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008; 29:16-21; PMID:18054800; http://dx.doi.org/10.1016/j.tips.2007.10.012.
12. Yu DS, Cortez D. A role for CDK9-cyclin K in maintaining genome integrity. Cell Cycle 2011; 10:28- 32; PMID:21200140; http://dx.doi.org/10.4161/ cc.10.1.14364.
13. Jessberger S, Gage FH, Eisch AJ, Lagace DC. Making a neuron: Cdk5 in embryonic and adult neurogenesis. Trends Neurosci 2009; 32:575-82; PMID:19782409; http://dx.doi.org/10.1016/j.tins.2009.07.002.
14. Lee JH, Kim HS, Lee SJ, Kim KT. Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J Cell Sci 2007; 120:2259-71; PMID:17591690; http://dx.doi.org/10.1242/jcs.03468.
15. Kasten M, Giordano A. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 2001; 20:1832-8; PMID:11313931; http://dx.doi.org/10.1038/sj.onc.1204295.
16. Sergère JC, Thuret JY, Le Roux G, Carosella ED, Leteurtre F. Human CDK10 gene isoforms. Biochem Biophys Res Commun 2000; 276:271-7; PMID:11006117; http://dx.doi.org/10.1006/bbrc.2000.3395.
17. Price DH. P-TEFβ, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000; 20:2629-34; PMID:10733565; http://dx.doi.org/10.1128/MCB.20.8.2629-34.2000.
18. Cho S, Schroeder S, Ott M. CYCLINg through transcription: posttranslational modifications of P-TEFβ regulate transcription elongation. Cell Cycle 2010; 9:1697-705; PMID:20436276; http://dx.doi.org/10. 4161/cc.9.9.11346.
19. Egly JM, Coin F. A history of TFIIH: two decades of molecular biology on a pivotal transcription/ repair factor. DNA Repair (Amst) 2011; 10:714-21; PMID:21592869; http://dx.doi.org/10.1016/j.dnarep.2011.04.021.
20. Lolli G. Binding to DNA of the RNA-polymerase II C-terminal domain allows discrimination between Cdk7 and Cdk9 phosphorylation. Nucleic Acids Res 2009; 37:1260-8; PMID:19136461; http://dx.doi.org/10.1093/nar/gkn1061.
21. Leucci E, De Falco G, Onnis A, Cerino G, Cocco M, Luzzi A, et al. The role of the Cdk9/Cyclin T1 complex in T cell differentiation. J Cell Physiol 2007; 212:411-5; PMID:17352406; http://dx.doi.org/10.1002/jcp.21032.
22. De Luca A, De Falco M, Baldi A, Paggi MG. Cyclin T: three forms for different roles in physiological and pathological functions. J Cell Physiol 2003; 194:101-7; PMID:12494448; http://dx.doi.org/10.1002/jcp.10196.
23. Falco GD, Neri LM, Falco MD, Bellan C, Yu Z, Luca AD, et al. Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines. Oncogene 2002; 21:7464-70; PMID:12386808; http://dx.doi.org/10.1038/sj.onc.1205967.
24. Fraldi A, Licciardo P, Majello B, Giordano A, Lania L. Distinct regions of cyclinT1 are required for binding to CDK9 and for recruitment to the HIV-1 Tat/ TAR complex. J Cell Biochem Suppl 2001; 247-53; PMID:11455589; http://dx.doi.org/10.1002/jcb.1149.
25. Simone C, Bagella L, Bellan C, Giordano A. Physical interaction between pRb and Cdk9/cyclinT2 complex. Oncogene 2002; 21:4158-65; PMID:12037672; http://dx.doi.org/10.1038/sj.onc.1205511.
26. Radhakrishnan SK, Gartel AL. CDK9 phosphorylates p53 on serine residues 33, 315 and 392. Cell Cycle 2006; 5:519-21; PMID:16552184; http://dx.doi. org/10.4161/cc.5.5.2514.
27. Claudio PP, Cui J, Ghafouri M, Mariano C, White MK, Safak M, et al. Cdk9 phosphorylates p53 on serine 392 independently of CKII. J Cell Physiol 2006; 208:602-12; PMID:16741955; http://dx.doi.org/10.1002/jcp.20698.
28. Napolitano G, Majello B, Licciardo P, Giordano A, Lania L. Transcriptional activity of P-TEFβ kinase in vivo requires C-terminal domain of RNA polymerase II. Gene 2000; 254:139-45; PMID:10974544; http:// dx.doi.org/10.1016/S0378-1119(00)00278-X.
29. Kim JB, Sharp PA. Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase. J Biol Chem 2001; 276:12317-23; PMID:11145967; http://dx.doi.org/10.1074/jbc.M010908200.
30. Lee DK, Duan HO, Chang C. Androgen receptor interacts with the positive elongation factor P-TEFβ and enhances the efficiency of transcriptional elongation. J Biol Chem 2001; 276:9978-84; PMID:11266437; http://dx.doi.org/10. 1074/jbc.M002285200.
31. Bark-Jones SJ, Webb HM, West MJ. EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5. Oncogene 2006; 25:1775-85; PMID:16314842; http://dx.doi.org/10.1038/sj.onc.1209205.
32. Zhou M, Lu H, Park H, Wilson-Chiru J, Linton R, Brady JN. Tax interacts with P-TEFβ in a novel manner to stimulate human T-lymphotropic virus type 1 transcription. J Virol 2006; 80:4781-91; PMID:16641271; http://dx.doi.org/10. 1128/JVI.80.10.4781-91.2006.
33. Durand LO, Roizman B. Role of Cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. J Virol 2008; 82:10591-9; PMID:18753202; http://dx.doi.org/10.1128/JVI.01242-08.
34. O'Keeffe B, Fong Y, Chen D, Zhou S, Zhou Q. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFβ-mediated tat stimulation of HIV-1 transcription. J Biol Chem 2000; 275:279-87; PMID:10617616; http://dx.doi.org/ 10.1074/jbc.275.1.279.
35. Simone C, Giordano A. Abrogation of signal-dependent activation of the Cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells. Cell Death Differ 2007; 14:192-5; PMID:16841087; http://dx.doi.org/10.1038/sj.cdd.4402008.
36. Bellan C, De Falco G, Lazzi S, Micheli P, Vicidomini S, Schürfeld K, et al. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol 2004; 203:946-52; PMID:15258998; http://dx.doi.org/10.1002/path.1588.
37. Moiola C, De Luca P, Gardner K, Vazquez E, De Siervi A. Cyclin T1 overexpression induces malignant transformation and tumor growth. Cell Cycle 2010; 9:3119-26; PMID:20714219; http://dx.doi.org/10.4161/cc.9.15.12526.
38. Foskett SM, Ghose R, Tang DN, Lewis DE, Rice AP. Antiapoptotic function of Cdk9 (TAK/P-TEFβ) in U937 promonocytic cells. J Virol 2001; 75:1220-8; PMID:11152495; http://dx.doi.org/10.1128/JVI.75.3.1220-8.2001.
39. Peng J, Zhu Y, Milton JT, Price DH. Identification of multiple cyclin subunits of human P-TEFβ. Genes Dev 1998; 12:755-62; PMID:9499409; http://dx.doi.org/10.1101/gad.12.5.755.
40. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106:2513-9; PMID:15972445; http://dx.doi.org/10.1182/blood-2005-04-1678.
41. Romano G, Prisco M, Zanocco-Marani T, Peruzzi F, Valentinis B, Baserga R. Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. J Cell Biochem 1999; 72:294-310; PMID:10022512; http://dx.doi.org/10.1002/ (SICI)1097-4644(19990201)72:2〈294:: AIDJCB14〉3.0.CO;2-0.
42. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19:7203-15; PMID:10490655.
43. Prisco M, Romano G, Peruzzi F, Valentinis B, Baserga R. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res 1999; 31:80-9; PMID:10226786; http://dx.doi.org/10.1055/s-2007-978703.
44. Pedersen MW, Pedersen N, Damstrup L, Villingshøj M, Sønder SU, Rieneck K, et al. Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation. J Cell Biochem 2005; 96:412-27; PMID:16075456; http://dx.doi.org/10.1002/jcb. 20554.
45. Lee JL, Lin CT, Chueh LL, Chang CJ. Autocrine/paracrine secreted Frizzled-related protein 2 induces cellular resistance to apoptosis: a possible mechanism of mammary tumorigenesis. J Biol Chem 2004; 279:14602-9; PMID:14709558; http://dx.doi.org/10.1074/jbc.M309008200.
46. Gelfanov VM, Burgess GS, Litz-Jackson S, King AJ, Marshall MS, Nakshatri H, et al. Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappaB-mediated antiapoptosis involving c-IAP2. Blood 2001; 98:2508-17; PMID:11588049; http://dx.doi.org/10.1182/blood.V98.8.2508.
47. Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget 2011; 2:610-26; PMID:21881167.
48. Hart JR, Vogt PK. Phosphorylation of AKT: a mutational analysis. Oncotarget 2011; 2:467-76; PMID:21670491.
49. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol-3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010; 1:89-103; PMID:20671809.
50. Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011; 10:2218-32; PMID:21623170; http://dx.doi.org/10.4161/cc.10.13. 16305.
51. Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN, et al. Survivin expression and its relation with proliferation, apoptosis and angiogenesis in brain gliomas. Cancer 2005; 104:2775-83; PMID:16284993; http:// dx.doi.org/10.1002/cncr.21490.
52. De Falco G, Bellan C, D'Amuri A, Angeloni G, Leucci E, Giordano A, et al. Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors. Cancer Biol Ther 2005; 4:277-81; PMID:15753651; http://dx.doi.org/10.4161/cbt.4.3.1497.
53. Balk SP, Knudsen KE. The cell cycle and prostate cancer. Nucl Recept Signal 2008; 6:1; PMID:18301781.
54. Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, et al. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007; 67:8325-34; PMID:17804748; http://dx.doi.org/10.1158/0008-5472.CAN-07-1826.
55. Boyer MJ, Cheng T. The CDK inhibitors: potential targets for therapeutic stem cell manipulations? Gene Ther 2008; 15:117-25; PMID:17989702; http:// dx.doi.org/10.1038/sj.gt.3303064.
56. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004; 3:1537-42; PMID:15539947; http:// dx.doi.org/10.4161/cc.3.12.1278.
57. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004; 64:3653-60; PMID:15150125; http://dx.doi. org/10.1158/0008-5472.CAN-04-0204.
58. Frey JA, Gandhi V. 8-Amino-adenosine inhibits multiple mechanisms of transcription. Mol Cancer Ther 2010; 9:236-45; PMID:20053765; http://dx.doi. org/10.1158/1535-7163.MCT-09-0767.
59. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009; 113:4637-45; PMID:19234140; http://dx.doi.org/10.1182/blood-2008-12-190256.
60. Canduri F, Perez PC, Caceres RA, de Azevedo WF Jr. CDK9 a potential target for drug development. Med Chem 2008; 4:210-8; PMID:18473913; http://dx.doi.org/10.2174/157340608784325205.
61. Krystof V, Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 2010; 11:291-302; PMID:20210754; http://dx.doi.org/10. 2174/138945010790711950.
62. Kobayashi M, Takahashi-Suzuki I, Shimomura T, Iwasawa Y, Hirai H. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor. Invest New Drugs 2011; 29:921-31; PMID:20524038; http://dx.doi.org/10.1007/s10637-010-9448-9.
63. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005; 24:7391-3; PMID:16288285; http://dx.doi.org/10.1038/sj.onc. 1209100.
64. Zhuang J, Hawkins SF, Glenn MA, Lin K, Johnson GG, Carter A, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica 2010; 95:110-8; PMID:19713228; http://dx.doi.org/10.3324/haematol.2009.010272.
65. Paoletti P, Vila I, Rifé M, Lizcano JM, Alberch J, Ginés S. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci 2008; 28:10090-101; PMID:18829967; http://dx.doi.org/10.1523/JNEUROSCI.3237-08.2008.
66. Hilton GD, Stoica BA, Byrnes KR, Faden AI. Roscovitine reduces neuronal loss, glial activation and neurologic deficits after brain trauma. J Cereb Blood Flow Metab 2008; 28:1845-59; PMID:18612315; http://dx.doi.org/10.1038/jcbfm. 2008.75.
67. Camins A, Verdaguer E, Folch J, Canudas AM, Pallàs M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 2006; 19:453-60; PMID:17160145; http://dx.doi.org/10.1358/dnp.2006.19.8.1043961.
68. Schmid G, Strosznajder JB, Wesierska-Gadek J. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors. Mol Neurobiol 2006; 34:27- 50; PMID:17003520; http://dx.doi.org/10.1385/MN:34:1:27.
69. Ramakrishnan R, Yu W, Rice AP. Limited redundancy in genes regulated by Cyclin T2 and Cyclin T1. BMC Res Notes 2011; 4:260; PMID:21791050; http:// dx.doi.org/10.1186/1756-0500-4-260.
70. Herrmann CH, Carroll RG, Wei P, Jones KA, Rice AP. Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J Virol 1998; 72:9881-8; PMID:9811724.
71. + T cells. Retrovirology 2006; 3:66; PMID:17014716; http://dx.doi.org/10.1186/1742-4690-3- 66.
72. Li HF, Kim JS, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 2009; 4:43; PMID:19828040; http://dx.doi.org/10.1186/1748-717X-4-43.
73. Sathornsumetee S. Therapeutic strategies to target multiple kinases in glioblastoma. Anticancer Agents Med Chem 2011; 11:700-11; PMID:21707500.
74. Suzuki M, Ishikawa H, Tanaka A, Mataga I. Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue. Hum Cell 2011; 24:21-9; PMID:21547692; http://dx.doi.org/10.1007/s13577-010-0004-x.
75. Brüning-Richardson A, Bond J, Alsiary R, Richardson J, Cairns DA, McCormack L, et al. ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br J Cancer 2011; 104:1602-10; PMID:21505456; http://dx.doi.org/10.1038/bjc.2011.117.
76. Goranova TE, Ohue M, Shimoharu Y, Kato K. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis 2011; 28:427-35; PMID:21380628; http://dx.doi.org/10.1007/s10585-011-9381-0.